Basic Information
| LncRNA/CircRNA Name | BLACAT2 |
| Synonyms | LINC00958 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | 5-FU | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, other |
| Sample | CRC tissues and cell lines (LOVO,SW620, HCT15, HCT116, SW480, DLD1) |
| Expression Pattern | up-regulated |
| Function Description | BLACAT2 was overexpressed in CRC cells and tissues, and high BLACAT2 expression was associated with larger tumor size, and more advanced lymph node (N), metastasis (M) and tumor-NM stages. Additionally, survival analysis demonstrated that patients with high BLACAT2 expression exhibited poor overall survival. Notably, high BLACAT2 expression was identified as an independent risk factor for overall survival. Migration and invasion assays revealed that BLACAT2 promoted migration and invasion, respectively. In addition, overexpression of BLACAT2 increased colony numbers and optical density values of CRC cells in a colony formation assay and an MTT assay, respectively. Furthermore, BLACAT2 levels were significantly increased in 5-fluorouracil-resistant cells, and overexpression of BLACAT2 was markedly associated with a low cell inhibition rate. |
| Pubmed ID | 31423277 |
| Year | 2019 |
| Title | Long Non-Coding RNA Bladder Cancer-Associated Transcript 2 Contributes to Disease Progression, Chemoresistance and Poor Survival of Patients With Colorectal Cancer |
External Links
| Links for BLACAT2 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |